当前位置: X-MOL 学术ACS Pharmacol. Transl. Sci. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
IL-33 in Chronic Respiratory Disease: From Preclinical to Clinical Studies
ACS Pharmacology & Translational Science ( IF 4.9 ) Pub Date : 2020-01-07 , DOI: 10.1021/acsptsci.9b00099
Chantal Donovan 1, 2 , Philip M. Hansbro 1, 2
Affiliation  

IL-33 has been deorphanized as a member of the IL-1 family and has key roles as an alarmin and cytokine with potent capacity to drive type 2 inflammation. This has led to a plethora of studies surrounding its role in chronic diseases with a type 2 inflammatory component. Here, we review the roles of IL-33 in two chronic respiratory diseases, asthma and chronic obstructive pulmonary disease (COPD). We discuss the hallmark and paradigm-shifting studies that have contributed to our understanding of IL-33 biology. We cover animal studies that have elucidated the mechanisms of IL-33 and assessed the role of anti-IL-33 treatment and immunization against IL-33. We highlight key clinical evidence for the potential of targeting increased IL-33 in respiratory diseases including exacerbations, and we outline current clinical trials using an anti-IL-33 monoclonal antibody in asthma patients. Finally, we discuss some of the challenges that have arisen in IL-33 biology and highlight potential future directions in targeting this cytokine in chronic respiratory diseases.

中文翻译:

IL-33在慢性呼吸系统疾病中的作用:从临床前到临床研究

IL-33已被孤立化为IL-1家族的一员,并具有强大的驱动2型炎症的作用,起着警报蛋白和细胞因子的关键作用。这导致围绕其在具有2型炎症成分的慢性疾病中的作用进行了大量的研究。在这里,我们回顾了IL-33在两种慢性呼吸系统疾病,哮喘和慢性阻塞性肺疾病(COPD)中的作用。我们讨论标志性和范式转换研究,这些研究有助于我们对IL-33生物学的理解。我们涵盖了阐明了IL-33的机制并评估了抗IL-33治疗和针对IL-33的免疫作用的动物研究。我们着重指出了关键的临床证据,这些证据针对的可能是在呼吸道疾病(包括病情加重,我们概述了目前使用抗IL-33单克隆抗体治疗哮喘患者的临床试验。最后,我们讨论了IL-33生物学中出现的一些挑战,并突出了针对这种细胞因子治疗慢性呼吸道疾病的潜在未来方向。
更新日期:2020-01-07
down
wechat
bug